- Maximum exposure for Curiox
- New product generation is entering the markets
- Business expansion in the US and Europe picks up momentum
Singapore / Palm Springs / Frankfurt – February 08, 2010 – Singapore-based Nanostart holding Curiox Biosystems Pte Ltd recently became the first Asian start-up company ever to be featured at LabAutomation’s prestigious Innovation AveNEW, an award program serving to highlight the industry’s most innovative emerging laboratory technologies.
Curiox was presented as one of eight elite start-ups, chosen from a pool of worldwide participants, at the Innovation AveNEW booth from January 25th to 27th.
LabAutomation is a premier industry event, known to be the world’s largest conference and exhibition focused on laboratory products and technologies in Life Sciences. The international recognition received at LabAutomation2010 is a great achievement for young start-up Curiox, which was selected by a panel of international industry experts from the Association for Laboratory Automation (ALA). Only a select few start-up companies are chosen for the Innovation AveNEW program each year.
The annual Innovation AveNEW program is currently in its fourth year, and serves to afford emerging, start-up companies the opportunity to actively engage and participate in a world-class event with more than 4.000 purchasing influencers and decision-makers of the laboratory automation from more than 40 countries.
In October 2009, Nanostart had increased its stake in Curiox Biosystems Pte Ltd, to almost 19% by a follow-up investment through its Nanostart Singapore Early Stage Venture Fund I. The investment was part of a second financing round, in which several experienced life science investors as well as a corporate investor joined as new investors in Curiox. Nanostart remains the lead investor. The funds help Curiox to tackle the therapeutics screening market for pharmaceutical and biotech firms. Having successfully established its semi-automated product, the DropArray™ LT, with customers from universities and government research laboratories in Singapore, the company is now introducing a new product line to the market and is expanding internationally, in particular to the USA and Europe. Curiox shall be maximizing the exposure received at LabAutomation2010 by highlighting its latest product, the DropArray™ Accelerator HT200, at the event. Presently, DropArray™ HT200 is being assessed by key market leaders in biotech and pharma.
“Curiox has managed to secure international and local excitement, with its revolutionary DropArray technology, in less than 2 years. This represents a significant milestone for Singapore, and is proof that Singapore-based biotech companies are able to compete on a global scale. This early achievement for Curiox was possible due to the ecosystem provided by Exploit Technologies and NUS Enterprise; as well as, the network and financial support offered by Nanostart Asia,” says Curiox’s CEO, Dr Namyong Kim.
For now, Curiox’s strategy is to establish itself in the research and screening markets with the DropArray™ HT200. Eventually, Curiox hopes to venture into the diagnostic and point-of-care markets, with its platform DropArray™ technology.
About Curiox Biosystems Pte Ltd:
Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox’s patented miniaturization platform, DropArray™, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time. The company is located in Singapore, the biomedical hub of Southeast Asia. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of Singapore’s Agency for Science, Technology and Research (A*STAR). For further information, please visit www.curiox.com.
About Nanostart:
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
